Cytori Therapeutics, Inc. (NASDAQ:CYTX) (Frankfurt:XMPA) entered
into a strategic equity agreement with Green Hospital Supply, Inc.
(TOKYO:3360), one of the leading medical equipment suppliers in Japan,
who will purchase 1.0 million shares of Cytori common stock at $6.00
per share. The transaction will close on or about April 12, 2007,
subject to satisfaction of customary closing conditions.
"With this equity position in Cytori, Green Hospital Supply is
making its first strategic investment in the emerging field of
regenerative medicine," said Mr. Kunihisa Furukawa, President of Green
Hospital Supply. "We have the required infrastructure and consulting
experience to effectively provide and integrate certain regenerative
medicine technologies, which may include cell preservation services,
to medical centers throughout Japan."
"This deal bolsters our cash position, adds another strategic
financial partner who shares our vision for regenerative medicine, and
allows us to maintain our focus on the development of therapeutic
applications for the Celution(TM) System and its near-term launch in
Europe," said Christopher J. Calhoun, chief executive officer of
Cytori Therapeutics. "We have jointly identified future collaborative
opportunities, which we look forward to further exploring."
About Green Hospital Supply, Inc.
Green Hospital Supply, Inc. (TOKYO:3360) operates three
businesses, which offer one-stop solutions for medical institutions in
Japan to optimize their hospital management. The Total Pack System
business offers solutions to meet the needs of clients to open,
relocate, add and/or renovate hospital facilities. Green Hospital
Supply continues the client relationships by selling medical practice
materials and consumables after hospitals start operations (Medical
Supply Business), and supplying meals and medical-related services
(Health Care Business). The Company strengthens ties with its clients
by making them business partners to further expand the spectrum of
businesses, for example, launching dispensing pharmacies near
hospitals (Health Care Business). http://www.ghs-inc.co.jp
About Cytori Therapeutics
Cytori Therapeutics is developing and seeks to commercialize stem
and regenerative cell therapies for cardiovascular disease,
reconstructive surgery and many other serious chronic, and life
threatening conditions. To provide these therapies, physicians remove
a small amount of a patient's fat, also known as adipose tissue, and
run it through Cytori's Celution(TM) System. This System quickly
separates and concentrates stem and regenerative cells from adipose
tissue so they may be quickly administered back to the patient about
an hour later. This system will dramatically improve the way in which
personalized cell-based therapies can be delivered to patients.
www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding
events, trends and prospects of our business, which may affect our
future operating results and financial position. Such statements are
subject to risks and uncertainties that could cause our actual results
and financial position to differ materially. Some of these risks and
uncertainties include our history of operating losses, the need for
further financing, regulatory uncertainties, dependence on performance
of third parties, and other risks and uncertainties described (under
the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual
report for the year ended December 31, 2005 and subsequent SEC
filings. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances
after the date they are made.
